SCHEMBL16765616

SCHEMBL16765616

CCOc1cc(=O)n(C)cc1-c1cc(NCc2c(F)cccc2F)ccc1Oc1ccc(F)cc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16765730 0.89 BRD4 (1.00) BRD4
SCHEMBL16765604 0.87 BRD4 (1.00) BRD4
SCHEMBL15552165 0.86 BRD4 (0.78) BRD4
SCHEMBL16765999 0.85 BRD4 (1.00) BRD4
SCHEMBL16765709 0.85 BRD4 (1.00) BRD4
SCHEMBL16766050 0.85 BRD4 (1.00) BRD4
SCHEMBL15553305 0.85 BRD4 (0.76) BRD4
SCHEMBL16765909 0.84 BRD4 (1.00) BRD4
SCHEMBL16765889 0.84 BRD4 (1.00) BRD4
SCHEMBL16766541 0.84 BRD4 (1.00) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3089970-B1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-17 EP claimed
US-10085985-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-10-02 US claimed
US-9428514-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-08-30 US claimed
US-20150158873-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-11 US claimed
US-20190008866-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-01-10 US disclosed
EP-3089970-B1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
US-10085985-B2 Bromodomain inhibitors ABBVIE INC. (US) 2018-10-02 US disclosed
US-20160331749-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-11-17 US disclosed
EP-3089970-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-11-09 EP disclosed
US-9428514-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-08-30 US disclosed
WO-2015089075-A1 DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2015-06-18 WO disclosed
US-20150158873-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10085985-B2 Bromodomain inhibitors BRD4, BRD3, BRD1 BRD4 1/4885
US-20190008866-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885
US-20160331749-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885
US-20150158873-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.